STOCK TITAN

Jaguar Health Q3 2026 product revenue falls 81.9%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Jaguar Health, Inc. (JAGX) reported third-quarter 2026 results, including total revenue of $2.343 million, down 24.0% from $3.083 million in Q3 2025. Product revenue was $551,000 versus $3.041 million, while license and grant revenue was $1.792 million versus $42,000.

Loss from operations was $6.023 million, compared with $7.238 million in Q3 2025; net loss was $5.830 million versus $9.648 million. Non-GAAP recurring EBITDA was a loss of $5.032 million, compared with $9.025 million, and non-GAAP EBITDA was a loss of $5.590 million versus $9.025 million. Jaguar says these non-GAAP measures are not substitutes for, or superior to, GAAP measures and should not be viewed in isolation.

Jaguar said it reduced its outstanding debt balance by $10.1 million in Q3 2026. Its rare-disease intestinal failure program for crofelemer powder for oral solution, targeting microvillus inclusion disease and short bowel syndrome, is expected to continue providing clinical milestones, including a planned NDA filing for MVID in mid-2027. Mytesi is indicated for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Major pointOutstanding debt declined by $10.1 million in Q3 2026. 1.8× market cap
  • Moderate pointNet loss narrowed 39.6% to $5.830 million in Q3 2026.

Negative

  • Moderate pointTotal revenue fell 24.0% to $2.343 million in Q3 2026.
  • Minor pointProduct revenue declined 81.9% to $551,000 in Q3 2026.

Filing Explained

The 8-K reports Jaguar’s third-quarter 2026 results; at September 30, 2026, cash was $5,528,000, equal to 103.2 days of the last reported quarterly operating cash use at that quarter’s rate.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $5,528,000 / ($4,929,000 / 92) = 103.2 days
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Total revenue $2.343 million Q3 2026; down 24.0% from $3.083 million in Q3 2025
Product revenue $551,000 Q3 2026; down 81.9% from $3.041 million in Q3 2025
License and grant revenue $1.792 million Q3 2026; compared with $42,000 in Q3 2025
Loss from operations $6.023 million loss Q3 2026; compared with a $7.238 million loss in Q3 2025
Net loss $5.830 million loss Q3 2026; 39.6% lower than the $9.648 million loss in Q3 2025
Non-GAAP recurring EBITDA $5.032 million loss Q3 2026; compared with a $9.025 million loss in Q3 2025
Debt reduction $10.1 million Reduction in outstanding debt balance during Q3 2026
Planned MVID NDA filing Mid-2027 Expected filing of an NDA for crofelemer for microvillus inclusion disease
Non-GAAP Recurring EBITDA financial
"Non-GAAP Recurring EBITDA"
Non-GAAP recurring EBITDA is an adjusted measure of a company’s ongoing operating profit that starts with earnings before interest, taxes, depreciation and amortization (EBITDA) and then removes one-time, irregular or special charges to show the business’s regular cash-generating performance. Investors use it like a household budget that ignores a one-off repair bill to see typical monthly expenses and income, helping compare underlying operations across periods, but it can vary by company because it is not standardized and may be shaped to look more favorable.
New Drug Application (NDA) regulatory
"planned New Drug Application (NDA) filing for crofelemer for MVID"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
microvillus inclusion disease (MVID) medical
"for microvillus inclusion disease (MVID)"
A rare, inherited disorder that appears in infants when cells lining the small intestine lack tiny hair‑like structures (microvilli), so the gut cannot absorb fluids and nutrients; this causes severe, life‑threatening diarrhea and often requires long‑term intravenous nutrition or other intensive care. For investors, MVID signals a clear unmet medical need that can make treatments, diagnostics or medical devices attractive targets for drug developers, diagnostic labs and specialty biotech firms because of potential regulatory incentives and high per‑patient value despite a small patient population.
intestinal failure medical
"rare disease intestinal failure development program"
Intestinal failure is a medical condition in which the gut cannot absorb enough nutrients, fluids, or electrolytes to keep a person healthy, so they need long‑term medical support such as intravenous nutrition or specialized feeding tubes. Think of the intestines as a conveyor belt that breaks down and delivers fuel to the body; when it fails, ongoing treatments, surgeries, and chronic care services become necessary. For investors, this creates steady demand for therapies, medical devices, home infusion services and related regulatory approvals that can drive revenue and long‑term contracts.
short bowel syndrome medical
"microvillus inclusion disease (MVID) and short bowel syndrome"
A chronic digestive disorder caused when a large portion of the small intestine is missing or not working, so the body cannot absorb enough nutrients and fluids from food. Investors should care because people with this condition often need long-term medical treatments, specialized nutrition or surgeries, and ongoing devices or drugs, creating sustained demand, higher healthcare costs, and opportunities for companies that provide therapies, supplies, or related services.
botanical guidance regulatory
"prescription drug under botanical guidance"
Botanical guidance is a set of regulatory recommendations and expectations from health authorities about developing, testing and approving products derived from plants. Think of it as a roadmap that explains what evidence — such as manufacturing consistency, safety and clinical data — regulators will want to see before allowing a botanical product to be marketed. For investors, this matters because clear guidance reduces regulatory uncertainty, shortens development timelines and helps gauge the likelihood and timing of commercial approval and revenue.
Total revenue $2.343 million Down 24.0% from $3.083 million in Q3 2025
Product revenue $551,000 Down 81.9% from $3.041 million in Q3 2025
License and grant revenue $1.792 million Up 4,166.7% from $42,000 in Q3 2025
Loss from operations $6.023 million loss 16.8% lower than the $7.238 million loss in Q3 2025
Net loss $5.830 million loss 39.6% lower than the $9.648 million loss in Q3 2025
Non-GAAP recurring EBITDA $5.032 million loss 44.2% lower than the $9.025 million loss in Q3 2025
Non-GAAP EBITDA $5.590 million loss 38.1% lower than the $9.025 million loss in Q3 2025
Guidance

Jaguar expects a planned NDA filing for crofelemer for MVID in mid-2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did JAGX revenue change in Q3 2026?

Jaguar Health reported total revenue of $2.343 million for Q3 2026, down 24.0% from $3.083 million in Q3 2025. Product revenue was $551,000, compared with $3.041 million a year earlier, while license and grant revenue was $1.792 million, up from $42,000.

When does JAGX expect to file an NDA for crofelemer for MVID?

Jaguar expects a planned New Drug Application filing for crofelemer for microvillus inclusion disease in mid-2027. The program is for crofelemer powder for oral solution and also targets short bowel syndrome as part of its rare-disease intestinal failure development program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001585608 0001585608 2026-11-16 2026-11-16
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Jaguar Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-36714   46-2956775

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

200 Pine Street

Suite 400

 
San Francisco, California   94104
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 371-8300

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 2.02

Results of Operations and Financial Condition.

On November 16, 2026, Jaguar Health, Inc. (the “Company”) issued a press release announcing the third quarter 2026 results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in any such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.
  

Description

99.1    Press Release, dated November 16, 2026.
104    Cover Page Interactive Data File (embedded within the inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      JAGUAR HEALTH, INC.
Date: November 16, 2026     By:  

/s/ Lisa A. Conte

     

Lisa A. Conte

Chief Executive Officer & President

Exhibit 99.1

 

LOGO

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027

Company significantly reduced outstanding debt balance by $10.1 million in Q3 2026

REMINDER: Jaguar to host investor webcast Tuesday, November 17, at 8:30 a.m. Eastern regarding Q3 2026 financials and company updates (click here to register)

SAN FRANCISCO, CA / November 16, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today reported its consolidated third-quarter 2026 financial results.

2026 THIRD QUARTER COMPANY FINANCIAL RESULTS:

 

  •  

License and Grant Revenue: Effective January 12, 2026, Jaguar entered a U.S. commercial licensing agreement with Woodward Specialty, LLC (“Woodward”), an affiliate of privately held Future Pak, LLC (“Future Pak”). Under the terms of the agreement, Future Pak is now the exclusive U.S. marketer for the Company’s Mytesi® and Canalevia®-CA1 products. The Company remains the manufacturer of Mytesi and Canalevia-CA1, supplying the products to Future Pak at cost-plus terms, and now operates as a distribution entity for Mytesi and Canalevia-CA1 with a primary focus on research and development efforts related to the Company’s late-stage development program for its powder-for-oral-solution formulation of crofelemer for rare-disease indications related to intestinal failure in humans. License revenues for the initial $16 million upfront payment, in addition to the $3 million payment for early termination of the Buy-Back Option, under the agreement with Future Pak were recognized by the Company in the first quarter of 2026. As announced in August 2026, Jaguar satisfied the closing conditions required to receive payment of the non-dilutive approximately $1.8 million holdback amount of the upfront fee from Future Pak. Additionally, the Company recognized license fees of $42,000 in the third quarter of 2026 from a securities purchase agreement with a European partner, which was supported by a binding term sheet. Approximately $42,000 of license fees were consistently recognized in each of the quarters of 2025 under this agreement. As of September 30, 2026, the total deferred revenue associated with this contract amounts to $425,000. There was no Federal grant revenue recognized in the third quarter of 2026 for the clinical study related to the treatment of chemotherapy-induced diarrhea (“CID”) in dogs and $25,000 in the nine-months ended September 30, 2026.

 

  •  

Prescription Product Revenue, Net: The total net revenue for the Company’s prescription products (Mytesi, Gelclair, and Canalevia-CA1) was approximately $0.5 million in the third quarter of 2026, which was comprised primarily of sales of Mytesi at cost-plus to Future Pak. In January 2026, Jaguar entered into a royalty-free license agreement with Future Pak. Under this agreement, all revenues generated in the United States from Mytesi and Canalevia-CA1, effective from January 12, 2026, are directed to Future Pak. Future Pak is privately held and does not report Mytesi sales. The decision to enter a commercial license agreement with Future Pak aligns with Jaguar’s strategic focus on advancing the development of its powder-for-oral-solution formulation of crofelemer for rare-disease indications related to intestinal failure in humans. The total net revenue for the Company’s prescription products in the second quarter of 2026 was approximately $1.2 million. Compared to the third quarter of 2025, the number of Mytesi bottles the Company sold in the third quarter of 2026 increased significantly and commercial costs were substantially decreased. Prescription products net revenue in the third quarter of 2025, when the Company had a salesforce and was focused on commercial sales of Mytesi, was approximately $3.0 million.


  •  

Neonorm™: Revenues for the non-prescription Neonorm products were consistent and minimal for the third quarters of 2026 and 2025.

 

Financial Highlights    Three Months Ending
September 30,
               
(in thousands, except per share amounts)    2026      2025      $ change      % change  

License and grant revenue, net

   $ 1,792      $ 42        1,750        4166.7 % 

Product revenue, net

     551        3,041        (2,490 )       -81.9 % 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue, net

     2,343        3,083        (740 )       -24.0 % 

Loss from operations

   $ (6,023 )     $ (7,238 )       1,215        16.8 % 

Net loss

   $ (5,830 )     $ (9,648 )       3,818        39.6 % 

Net loss per share, basic and diluted

   $ (9.23 )     $ (2,032.95 )       2,024        99.5 % 

 

  •  

Cost of Product Revenue: The total cost of product revenue increased by $0.1 million, from $0.5 million for the quarter ended September 30, 2025 compared to about $0.6 million for the quarter ended September 30, 2026. The increase in cost was due to sales of inventory to Future Pak in the third quarter of 2026 under the licensing and supply agreement and Gelclair royalty expense.

 

  •  

Research and Development: The R&D expense decreased by approximately $0.1 million, from $3.7 million for the quarter ended September 31, 2025 compared to $3.6 million for the quarter ended September 30, 2026. The cost increase of $0.8 million for clinical trials and the development of crofelemer into a powder formulation, a process called lyophilization, was offset by a decrease of $0.9 million due to reductions in force (RIF), third-party consulting and other expense due to conclusion of the CTD Phase 3 clinical trial.

 

  •  

Sales and Marketing: The Sales and Marketing expense decreased by approximately $1.95 million, from $2.0 million for the quarter ended September 31, 2025 to approximately $51,000 for the quarter ended September 30, 2026. The decrease was due to the dissolution of the Jaguar/Napo Sales and Marketing Group as of January 12, 2026 following the licensing of Mytesi and Canalevia-CA1 to Future Pak.

 

  •  

General and Administrative: The G&A expense decreased by approximately $55,000, from $4.1 million in the quarter ended September 31, 2025 to $4.0 million in the quarter ended September 30, 2026. Overall, the increase in the total cost of legal and public services, audit, accounting and tax services, and stock-based compensation of $0.6 million was offset by a decrease in consulting, lease, travel and other expense totaling $0.7 million.

 

  •  

Loss from Operations: The loss from operations decreased $1.2 million, going from a loss of $7.2 million in the quarter ended September 31, 2025, to a loss of $6.0 million in the quarter ended September 30, 2026. This change was primarily due to a $0.7 million decrease in total net revenue, which was offset by a reduction in operating expenses of approximately $2.0 million, attributed to the Future Pak licensing agreement.

 

  •  

Net Loss: Net loss decreased by approximately $3.8 million, from a loss of $9.6 million in the quarter ended September 31, 2025 to a loss of $5.8 million in the quarter ended September 30, 2026. In addition to the loss from operations:

 

  •  

Interest expense increased by $150,000, from $6,000 of interest income for the quarter ended September 31, 2025 to $156,000 in the quarter ended September 30, 2026, due to interest expenses accrued on notes.


  •  

The fair value of financial and hybrid instrument designation at Fair Value Option (“FVO”) decreased by about $2.2 million, from a loss of $2.3 million in the quarter ended September 31, 2025, to a loss of $96,000 in the same period in 2026, primarily due to lower outstanding carrying amounts of royalty interests, and notes payable designated at FVO relative to their fair values, resulting in lower fair value changes during the period.

 

  •  

Gain on extinguishment of debt increased by $0.6 million from $0 in the three months ended September 30, 2025, to $0.6 million in the same period in 2026. The increase was primarily attributable to the extinguishment of the Streeterville New Note, following the Company’s exchange transaction, in which the Company issued shares of its common stock to Streeterville, resulting in the full repayment and cancellation of the Streeterville New Note.

 

  •  

Non-GAAP Recurring EBITDA: Non-GAAP Recurring EBITDA for the third quarters of 2026 and 2025 were a net loss of approximately $5.0 million and $9.0 million, respectively.

 

     Three Months Ending
September 30,
               
(in thousands)    2026      2025      $ change      % change  
     (unaudited)                

Net loss

   $ (5,830 )     $ (9,648 )       3,818        39.6 % 

Adjustments:

           

Interest income (expense)

     156        6        150        2500.0 % 

Property and equipment depreciation

     6        14        (8 )       -57.1 % 

Amortization of intangible assets

     468        468        —         0.0 % 

Share-based compensation expense

     168        135        33        24.4 % 
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP Recurring EBITDA

     (5,032 )       (9,025 )       3,993        44.2 % 

Gain on extinguishment of debt

     (558 )       —         (558 )       -100.0 % 
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP EBITDA

   $ (5,590 )     $ (9,025 )       3,435        38.1 % 

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.


About the Jaguar Health Family of Companies

Jaguar Health, Inc. (“Jaguar”) develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Gelclair®

INDICATIONS

GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.

IMPORTANT SAFETY INFORMATION

 

  •  

Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.

 

  •  

No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.

 

  •  

If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.

 

  •  

If no improvement is seen within 7 days, a physician should be consulted.

You are encouraged to report negative side effects of prescription medical products to the FDA.

Visit www.fda.gov/safety/medwatch or call 1-855-273-0468.

Please see full Prescribing Information at:

https://www.gelclairhcp.com/pdf/prescribing-information-instructions-for-use.pdf

Important Safety Information About Canalevia®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.


Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

See full Prescribing Information at Canalevia.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the Company will file a New Drug Application (NDA) with the U.S. Food and Drug Administration for crofelemer for MVID in mid-2027, and Jaguar’s expectation that it will hold an investor webcast on November 17, 2026. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

hello@jaguar.health

Jaguar-JAGX

Filing Exhibits & Attachments

4 documents

Keep reading